Hemab Therapeutics Holdings, Inc. Common Stock (COAG) — Financial Flexibility Index

Latest as of December 2025: -0.17x

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) has a Financial Flexibility Index of -0.17x as of December 2025. Free cash flow of $-61.46 Million (operating CF $-61.48 Million minus capex $16.00K) represents 0% of total liabilities ($371.42 Million). Check Hemab Therapeutics Holdings, Inc. Common (COAG) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Financial Flexibility Index

-0.17x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-61.46 Million
Operating CF − Capex

Total Liabilities

$371.42 Million
USD

Capital Expenditures

$16.00K
USD

Hemab Therapeutics Holdings, Inc. Common Stock Financial Flexibility Index (2024–2025)

Historical Financial Flexibility Index trend for Hemab Therapeutics Holdings, Inc. Common Stock across 2 annual periods. See working capital position of Hemab Therapeutics Holdings, Inc. Common to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for Hemab Therapeutics Holdings, Inc. Common Stock (2024–2025)

Year-by-year free cash flow to debt coverage for Hemab Therapeutics Holdings, Inc. Common Stock. For the full company profile including market capitalisation, see COAG stock market capitalisation.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -0.17x $-61.46 Million $-61.48 Million $371.42 Million ▲ +22.7%
2024 -0.21x $-45.31 Million $-45.59 Million $211.55 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities